Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Aditya Arra, Maximilian Pech, Hang Fu, Holger Lingel, Franziska Braun, Christian Beyer, Myra Spiliopoulou, Barbara M. Bröker, Karen Lampe, Christoph Arens, Katrin Vogel, Mandy Pierau, Monika C. Brunner-Weinzierl
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2021-01-01
Serier:	OncoImmunology
Fag:	ctla-4 adults neonates children cd40l multifunctional t-cells s. aureus
Online adgang:	http://dx.doi.org/10.1080/2162402X.2021.1938475
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!